The market for duloxetine API is expected to grow at a CAGR of around 4.1% from 2020 to 2027 and expected to reach the market value of around US$ 4,204.7 Mn by 2027.
Duloxetine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is used to treat depression and anxiety. Particularly, it is used to help in relieving nerve pain in people with diabetes or ongoing pain due to medical conditions such as arthritis or chronic back pain. Duloxetine can also improve mood, sleep, appetite, and energy level, and decrease nervousness. This can also decrease pain due to certain medical conditions. Active pharmaceutical ingredients (APIs) are used in the manufacturing of pharmaceutical dosage forms such as tablets and capsules.
The growing prevalence of depression along with the increasing cases of anxiety are some of the factors driving the market growth. The increasing penetration of generic drugs, the growing trend of outsourcing, strong drug pipeline, as well as growing demand for newly developed branded drugs is bolstering the market value. Furthermore, the emerging economies and their respective efforts for the advancement in the field in order to provide advanced solutions to the conditions are projected to create potential opportunities over the forecast period from 2020 to 2027.
On the other hand, changes in cost structure are likely to limit the growth to an extent over the forecast period from 2020 to 2027.
North America accounted for the maximum revenue share in the global duloxetine API market
In 2019, North America registered maximum revenue share (%) in the duloxetine API market, and the region is also projected to maintain its dominance over the forecast period from 2020 to 2027. The well-established healthcare infrastructure and developed economies of the region are supporting the regional market value. The increasing cases of diabetes in the region are propelling the regional market growth. The presence of major manufacturers in the region and their efforts for continuous advancement in the region is further bolstering the regional market value. Chronic musculoskeletal pain is one of the most frequent painful complaints addressed by the healthcare providers where duloxetine API is recommended by the doctors. Chronic low back pain and chronic osteoarthritis are also among the most common form of arthritis in the US.
Asia Pacific is projected to experience fastest growth throughout the forecast period
Asia Pacific along with its developing economies is projected to experience the fastest growth with a major CAGR (%) during the forecast period from 2020 to 2027. The major economies of the region including Japan, China, and India are bolstering the regional market growth. The increasing investment by the major players in the research & development activities in the healthcare sector of the region in order to take advantage of available opportunities is accelerating the regional market value. The high prevalence of mental disorders and neurological diseases due to hectic work-life schedules and rising trend of unhealthy eating habits are further accelerating the regional market value. The presence of large number of manufacturers in the region is supporting the regional market value.
Key Market Players
The players profiled in the report include Apotex Inc. (Canada), Aurobindo Pharma (India), Eli Lilly and Company (US), Hetero (India), Lupin (India), Shionogi Inc. (US), Shodhana Laboratories (India), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Zhejiang Huahai Pharmaceutical Co. Ltd. (China), and Zydus Cadila (India). The major market players were involved in mergers and acquisitions, partnerships & collaborations, and new source development for the expansion of market share.
Market By Type of Drug
Market By Product Type
Major Depressive Disorder
Generalized Anxiety Disorder
Chronic Musculoskeletal Pain
Market By Application
Pharmaceutical and BioApplication Industries
Market By Geography
Middle East & Africa
The market for duloxetine API is expected to reach a market value of around US$ 4,204.7 Mn by 2027.
The duloxetine API market is expected to grow at a CAGR of around 4.1% from 2020 to 2027.
The growing prevalence of depression, increasing cases of anxiety, increasing penetration of generic drugs, growing trend of outsourcing, strong drug pipeline, and growing demand for newly developed branded drugs are some of the key factors driving the global duloxetine API market growth.
Apotex Inc. (Canada), Aurobindo Pharma (India), Eli Lilly and Company (US), Hetero (India), Lupin (India), Shionogi Inc. (US), Shodhana Laboratories (India), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Zhejiang Huahai Pharmaceutical Co. Ltd. (China), and Zydus Cadila (India) are the prominent players in the market.
North America held the highest market share in the duloxetine API market
Asia Pacific is expected to be the fastest growing market over the forecast period
In Type of Drug segment the Generic segment is growing at faster pace.